What is Ablative Solutions?
Founded in 2011 and based in Wakefield, MA, Ablative Solutions is dedicated to addressing the unmet medical need of hypertension. The company's innovative approach targets the overactive sympathetic nervous system, a pathway implicated in various conditions including hypertension, heart failure, kidney disease, metabolic syndrome, and sleep apnea. Their flagship technology, the Peregrine System, is currently under investigation as a complementary treatment for hypertension when used alongside existing antihypertensive medications. This strategic financing positions Ablative Solutions to advance its clinical development and commercialization efforts in the significant cardiovascular health market.
How much funding has Ablative Solutions raised?
Ablative Solutions has raised a total of $149.8M across 9 funding rounds:
Debt
$3M
Series A
$5.4M
Debt
$8M
Series B
$9.5M
Series C
$14.6M
Unspecified
$2.5M
Private Equity
$11.4M
Debt
$4M
Series D
$91.4M
Debt (2011): $3.1M, investors not publicly disclosed
Series A (2012): $5.4M led by Michigan Accelerator Fund and BioStar Capital
Debt (2013): $8M, investors not publicly disclosed
Series B (2014): $9.5M featuring BioStar Capital and Michigan Accelerator Fund I
Series C (2015): $14.6M, investors not publicly disclosed
Unspecified (2015): $2.5M, investors not publicly disclosed
Private Equity (2017): $11.4M, investors not publicly disclosed
Debt (2017): $4M, investors not publicly disclosed
Series D (2022): $91.4M featuring Gilde Healthcare, Invus Opportunities, and BioStar Capital
Key Investors in Ablative Solutions
Gilde Healthcare
Gilde Healthcare is a specialized healthcare investment firm managing over €1.4 billion across three fund strategies: Venture & Growth in Healthcare, Private Equity in Healthcare, and Private Equity in Climate Solutions. The firm focuses on investing in businesses that enable better care at lower costs and address planetary challenges through energy transition, biodiversity, and waste management. With a portfolio that includes healthtech, therapeutics, and climate-related companies, Gilde Healthcare aims to support impactful solutions in both sectors. Headquartered in Utrecht, the Netherlands, with offices in Frankfurt, Germany, and Boston, USA, Gilde Healthcare serves clients in the healthcare and climate sectors.
BioStar Capital
BioStar Capital is a visionary healthcare investor focused on transformative medical devices. The company combines business acumen with clinical expertise, leveraging a collaboration of healthcare clinicians, medical thought leaders, and financial professionals. With over two decades of experience, BioStar Capital is dedicated to producing life-changing outcomes for patients while delivering rewarding returns for investors. Their portfolio showcases innovations that have a significant impact on the medical technology landscape.
Michigan Accelerator Fund
The purpose of Michigan Accelerator Fund 1 is to achieve significant, long-term capital appreciation for its investors through investments in Michigan-based, early stage companies predominantly in the healthcare and life science sectors.
What's next for Ablative Solutions?
The substantial enterprise-level backing, particularly the recent strategic investment, indicates Ablative Solutions is likely in a scaling phase, aiming to expand its market reach and further validate its therapeutic technology. This capital infusion is expected to accelerate the clinical trial process for the Peregrine System and support regulatory submissions. The company's focus on a prevalent condition like hypertension, coupled with its novel approach, suggests a strong potential for future growth and market penetration. Continued investment in this area underscores the significant opportunities within the interventional cardiology and hypertension management sectors.
See full Ablative Solutions company page
